

It follows announcements of top-line data from the ENHANCE-1 and ENHANCE-2 trials in December and August 2022, respectively.ĭata from the ENHANCE program formed the basis of Verona Pharma’s New Drug Application (“NDA”), which was submitted in June 2023 to the US Food and Drug Administration (“FDA”) for the approval of ensifentrine for the maintenance treatment of patients with COPD.Įnsifentrine is a selective dual inhibitor of the enzymes phosphodiesterase 3 and 4, combining bronchodilator and non-steroidal anti-inflammatory activities in one molecule.

The manuscript, entitled ‘Ensifentrine, a Novel PDE3 and PDE4 Inhibitor for the Treatment of COPD: Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Trials (The ENHANCE Trials)’, is available online here and will be published in an upcoming issue of AJRCCM. The publication reports results from Verona Pharma’s successful ENHANCE trials demonstrating improvements with ensifentrine in lung function, symptoms and quality of life measures, as well as a substantial reduction in the rate and risk of COPD exacerbations and a favourable safety profile. LONDON and RALEIGH, N.C., J(GLOBE NEWSWIRE) - Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces the American Journal of Respiratory and Critical Care Medicine (“AJRCCM”) has published results from its Phase 3 ENHANCE trials evaluating ensifentrine in chronic obstructive pulmonary disease (“COPD”).
